EGFR and urothelial carcinoma: Our previous study showed that the antitumor effect of lapatinib in canine urothelial carcinoma cell lines is associated with HER2 expression, but not with EGFR expression23, therefore we evaluated HER2 status as a biomarker for response to lapatinib in this canine trial.